Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYO-FMT for Induction of Remission in Active Ulcerative Colitis
NCT04202211Phase 2Withdrawn
- Sponsor
- University of British Columbia
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fecal Microbiota Transplantation Capsule in ulcerative colitis (UC) (3 arms), sponsored by University of British Columbia. Primary endpoint: Remission of Ulcerative Colitis at 9 weeks. Planned start Mar 2022; status: withdrawn.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04202211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202211.